CoEN 2017-18 funded projects:
- Glypican4 as a target for innovative cell-based replacement therapy and as a biomarker in Parkinson’s disease
Rosanna Dono (France), Mathias Bähr (Germany) - Carbon-Model: Carbon metabolism systems analysis for the identification of disease and patient-specific metabolic and energetic defects in neurodegenerative diseases
Jochen Prehn (Republic of Ireland), Daniele Bano (Germany) - Neuropathological and Amyloid peptides differences between Down syndrome and familial Alzheimer’s disease with duplications and missense mutations in APP gene
Marie-Claude Potier (France), Andre Strydom (UK), Henrik Zetterberg (UK) - Gut microbes, Neuroinflammation and Alzheimer’s disease: determining the immunoregulatory role of gut microbiota on brain and behaviour
Yvonne Nolan (Republic of Ireland), Annamaria Cattaneo (Italy), Sandrine Thuret (UK) - Developing preclinical and clinical biomarkers of NRF2 pathway activation for therapeutic application in neurodegenerative diseases
Pamela Shaw (UK), Antonio Cuadrado (Spain) - Investigating chromatin landscapes in neurodegenerative disease models
Paola Salomoni (Germany), Giovanna Mallucci (UK) - Is prion like propagation of alpha synuclein aggregation associated with a ferroptotic cell death
David Devos (France), Alexander Storch (Germany), Nicola Pavese (UK) - Investigating the interaction between ageing and immune dysfunction in LRRK2 Parkinson’s disease
Michela Deleidi (Germany), Francesca L’Episcopo (Italy) - Focused ultrasound modulation of neuromelanin accumulation in a humanized rat model of Parkinson’s disease
Miquel Vila (Spain), Stéphane Lehericy (France)
More information can be obtained at www.coen.org